Dogwood Therapeutics, Inc. $DWTX

What the company doesAI summary of filing

Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company focused on developing medicines to treat pain and neuropathy. The company's lead program, Halneuron®, is a non-opioid sodium channel modulator based on tetrodotoxin that is in late-stage clinical development for chemotherapy-induced neuropathic pain, with a Phase 2b trial ongoing as of the filing date. The company also develops SP16, a synthetic peptide for treating chemotherapy-induced peripheral neuropathy, which is in early Phase 1 development with National Cancer Institute funding. Additionally, Dogwood has antiviral programs including IMC-1 and IMC-2 for conditions such as fibromyalgia and Long-COVID, though these are being pursued through external partnerships. The company generates no revenue and relies on third parties for manufacturing and clinical trial operations. [10-K 2026-03-18]

Segments: Halneuron® (tetrodotoxin for neuropathic pain), SP16 (serpin peptide for chemotherapy-induced neuropathy), IMC-1 (famciclovir + celecoxib for fibromyalgia), IMC-2 (valacyclovir + celecoxib for Long-COVID)